+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effects of three different doses of AZD8965 compared to a placebo in adults aged 40 and older with Idiopathic Pulmonary Fibrosis IPF. This Phase IIb study aims to assess how well AZD8965 works, its safety, and how well participants tolerate it. Participants include those on stable doses of approved antifibrotic therapies and those not receiving such treatments. Participants will be randomly assigned to one of four groups placebo, low dose, medium dose, or high dose of AZD8965. The study lasts 24 weeks and is conducted globally at approximately 200 sites. This is a double-blind, placebo-controlled, parallel-group study, meaning neither participants nor researchers know which treatment any participant receives during the trial. During the study, participants will have their lung function measured by changes in forced vital capacity FVC at 24 weeks, along with monitoring for safety through the recording of adverse events. Additional assessments include examining the relationship between dose and efficacy, rate of lung function decline, and pharmacokinetics of AZD8965. The total participation time is 24 weeks with safety follow-up up to 25 weeks.

Age: 40Years +All GendersPhase 2
198 locations
R

Actively Recruiting

Researchers are evaluating saruparib AZD5305 added to standard radiation therapy RT and androgen deprivation therapy ADT compared to placebo in men with high-risk and very high-risk localized or locally advanced prostate cancer who have a BRCA1 or BRCA2 gene mutation. This Phase III randomized, double-blind, placebo-controlled study aims to assess whether saruparib improves metastasis-free survival in this specific group of patients. Participants will be divided into two groups Cohort A includes men with newly diagnosed high-risk prostate cancer or high-risk biochemical recurrence after radical prostatectomy, receiving saruparib or placebo with ADT Cohort B includes men with very high-risk prostate cancer receiving saruparib or placebo combined with ADT plus abiraterone and prednisoloneprednisone. Saruparib and placebo are given orally, alongside standard treatments, and participants will receive the treatment and follow-up according to their assigned cohort. During the study, participants will undergo scans including CT or MRI, bone scans, and PSMA-PET to monitor disease status. Researchers will track survival outcomes, metastasis-free survival up to about 93 months, and overall survival up to 11 years. Blood samples will measure drug concentrations, and safety will be monitored through adverse event reporting. Participants will be followed until the study ends, with ongoing assessments to evaluate treatment effects and safety.

Age: 18Years +MALEPhase 3
346 locations
R

Actively Recruiting

Researchers are evaluating whether spesolimab helps adults with ulcerative pyoderma gangrenosum PG, a skin condition causing ulcers. The study focuses on whether spesolimab leads to the closure of PG ulcers and compares this with a placebo. This phase 3 clinical trial is randomized, double-blind, and placebo-controlled, enrolling adults with at least one ulcer between 5 cm and 80 cm in size. Participants are randomly assigned to receive either spesolimab or a placebo infusion every 4 weeks. In the first part of the study, all participants also take corticosteroid medicine by mouth for 8 weeks. In the second part, those without open ulcers are again randomly assigned to spesolimab or placebo, while participants with open ulcers receive spesolimab. The study includes two treatment phases to evaluate the effects under different conditions. Participants stay in the trial for about 1.5 years, attending around 20 study visits. During visits, doctors examine the skin for signs of PG, monitor overall health, and watch for any side effects. The main outcome is the complete closure of the target PG ulcer up to week 26, confirmed at a later visit. Secondary outcomes include pain reduction and quality of life improvements. The study compares results between groups to assess the treatments impact and monitors participants safety throughout.

Age: 18Years +All GendersPhase 3
104 locations
E

Actively Recruiting

Researchers are evaluating zongertinib, an oral HER2-targeted drug, to see if it can improve outcomes compared to standard adjuvant treatments in adults with completely removed Stage II to IIIB non-small cell lung cancer NSCLC that has activating HER2 tyrosine kinase domain mutations. This Phase 3, global, randomized, open-label study includes participants who have had surgery with curative intent and received perioperative systemic therapy such as neoadjuvant platinum-based chemotherapy with or without immunotherapy, or adjuvant platinum-based chemotherapy. Participants are randomly assigned to one of two groups one group takes zongertinib daily by mouth for up to three years, while the other group follows standard care, which may include approved adjuvant immunotherapy or observation based on local guidelines and patient condition. This comparison aims to determine if zongertinib can extend disease-free survival. Safety, overall survival, tolerability, and patient-reported outcomes are also monitored during the study. During the study, participants undergo regular evaluations including disease assessments by investigators for up to 8 years and 5 months to measure disease-free survival and overall survival. Safety is tracked by recording adverse events, especially those of grade 3 or higher, from treatment start through up to three years or tumor recurrence. Participants provide tumor tissue samples for HER2 status confirmation, and their overall health and organ functions are monitored. The entire study lasts several years, including follow-up to assess long-term outcomes.

Age: 18Years +All GendersPhase 3
203 locations
S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
E

Actively Recruiting

Researchers are investigating the use of mocravimod as an additional and maintenance treatment for adults with acute myeloid leukemia AML who are undergoing allogeneic hematopoietic cell transplantation HCT. This phase III, multi-center, randomized, double-blind, placebo-controlled trial aims to assess the drugs safety and effectiveness in this patient population, focusing on improving relapse-free survival. Participants will be randomly assigned to one of three groups receiving 3 mg of mocravimod daily, 1 mg of mocravimod daily, or a placebo daily, all administered orally for 12 months. The study involves parallel groups and maintains quadruple masking to ensure unbiased results. During the trial, participants will be closely monitored with regular assessments to evaluate relapse-free survival over 12 months and overall survival over 24 months. Safety and efficacy will be observed throughout, with participants undergoing standard care alongside study treatments. The total participation duration aligns with the treatment and follow-up periods extending up to two years.

Age: 18Years - 75YearsAll GendersPhase 3
111 locations
R

Actively Recruiting

Researchers are evaluating the overall survival of patients with stage I epithelial ovarian cancer after they have undergone comprehensive staging surgery. This phase III trial compares the outcomes of adjuvant chemotherapy versus observation alone. The study aims to determine whether adding chemotherapy after surgery improves survival in this patient group. Participants will be randomly assigned to one of two groups. One group receives adjuvant chemotherapy, which includes either a combination of paclitaxel and carboplatin or docetaxel and carboplatin, given every three weeks for three to six cycles. Switching between paclitaxel and docetaxel is allowed if adverse events occur. The other group undergoes observation without chemotherapy. During the study, participants will be monitored for overall survival up to 60 months from randomization. Researchers will also assess relapse-free survival within the same timeframe. Evaluations include follow-ups to track disease progression, side effects, and general health. The study ensures participants receive appropriate care and measures outcomes to better understand treatment benefits and risks.

Age: 20Years +FEMALEPhase 3
103 locations
L

Actively Recruiting

Spinal muscular atrophy SMA is a genetic disorder caused by changes in the SMN1 gene, leading to low SMN protein levels and problems with motor neurons. It is an inherited disease that mainly affects children and is a leading cause of infant death due to genetic conditions. This research aims to observe patients with SMA over time to understand long-term outcomes with new treatments and to evaluate the long-term safety and effects of the investigational therapy OAV-101. This is a prospective, multinational, non-interventional observational study where patients receive their usual clinical care without changes directed by the study. Treatments such as Zolgensma may be given according to normal clinical practice, but this is not controlled by the study protocol. Patients will be followed for up to 15 years or until death, with no extra visits or tests beyond what is normally done for SMA care. Participants will be evaluated through regular clinical assessments based on their normal care schedule, with data collected at baseline and at intervals of every 6 months for the first 2 years, then yearly for up to 15 years. Researchers will measure survival rates, motor function scores like CHOP-INTEND and HFMSE, hospitalizations, quality of life, use of ventilator, nutritional, and mobility supports, as well as any treatment-related side effects during this long-term follow-up.

All AgesAll Genders
99 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of sonesitatug vedotin combined with capecitabine, with or without rilvegostomig, as a first treatment option for adults with Claudin18.2-positive, HER2-negative advanced or metastatic gastric, gastroesophageal junction GEJ, and esophageal adenocarcinoma. This Phase III study includes two participant groups based on PD-L1 status and eligibility for immune checkpoint inhibitors ICI, aiming to provide treatment options tailored to these specific cancer characteristics. Participants receive different combinations of study drugs depending on their cohort Cohort 1 gets sonesitatug vedotin with rilvegostomig and capecitabine if PD-L1 positive and ICI eligible, while Cohort 2 receives sonesitatug vedotin with capecitabine if PD-L1 negative or ICI ineligible. Other treatment arms include combinations with nivolumab and zolbetuximab alongside standard chemotherapy regimens. All drugs are administered intravenously or orally as specified, with the study also assessing the clinical performance of diagnostic tests related to these treatments. Throughout the study, participants undergo regular assessments to monitor disease progression, survival, response to treatment, drug levels in the body, immune responses, and safety over approximately five years. Researchers use imaging and laboratory tests to evaluate tumors and organ function, and participants health status is closely observed. The study involves random assignment to treatment groups and includes ongoing safety and effectiveness evaluations during and after treatment.

Age: 18Years +All GendersPhase 3
314 locations
R

Actively Recruiting

Plaque psoriasis is a chronic inflammatory skin condition that causes thick, red, and scaly patches. This research evaluates how treatment with risankizumab affects the quality of life in adults with moderate to severe plaque psoriasis in real-world clinical settings. About 700 participants prescribed risankizumab by their doctors according to local guidelines will be involved in this study. Participants will receive risankizumab as directed by their physicians based on routine care and local labeling. There are no additional treatments or study drugs provided beyond what is normally prescribed. The study is observational and follows participants for up to 2.5 years while they continue their usual treatment. During the study, participants will attend regular visits at hospitals or clinics as part of their standard care. Researchers will assess outcomes such as the proportion of participants achieving a Dermatology Life Quality Index DLQI score of 0 or 1 at 12 months. The study aims to understand the impact of risankizumab on quality of life with minimal extra burden to participants.

Age: 18Years +All Genders
84 locations

1-10 of 11

1